Similarly, tumor sizes in C57BL/6 mice bearing Hepa1–6 cells were significantly smaller in groups receiving anti-FGL2 treatment (Fig. 1c) or harboring the Fgl2 knockout (Fig. 1d) as compared with controls. This evidence concerns the gene FGL2 and neoplasm.